Today, China Biologic Products Inc. (CBPO) Downgraded by Zacks Investment Research to “Hold”

Today, China Biologic Products Inc. (CBPO) Downgraded by Zacks Investment Research to “Hold”

Zacks Investment Research lowered shares of China Biologic Products Inc. (NASDAQ:CBPO) from a buy rating to a hold rating in a research report released on Tuesday.

According to Zacks, “China Biologic Products, Inc., through its indirect majority-owned subsidiary, is principally engaged in the research, development, production, manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. Its subsidiary, Shandong Taibang Biological Products Co. Ltd., operates from its manufacturing facility located in Taian City, Shandong Province. The Company’s principal products include its approved human albumin and immunoglobulin products. These human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases. “

A number of other equities analysts also recently commented on CBPO. Credit Suisse Group AG upgraded China Biologic Products from a neutral rating to an outperform rating in a report on Tuesday, July 5th. Jefferies Group increased their target price on China Biologic Products from $136.00 to $155.00 and gave the company a buy rating in a research note on Friday, August 5th.

Shares of China Biologic Products (NASDAQ:CBPO) opened at 117.01 on Tuesday. China Biologic Products has a 52 week low of $95.70 and a 52 week high of $144.29. The stock has a market cap of $3.15 billion, a PE ratio of 33.74 and a beta of 1.55. The firm has a 50-day moving average price of $119.92 and a 200-day moving average price of $117.34.

China Biologic Products (NASDAQ:CBPO) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported $1.26 EPS for the quarter, topping analysts’ consensus estimates of $1.16 by $0.10. The company had revenue of $91.40 million for the quarter, compared to the consensus estimate of $87.60 million. China Biologic Products had a return on equity of 19.65% and a net margin of 29.66%. The company’s quarterly revenue was up 15.6% compared to the same quarter last year. During the same period last year, the business posted $1.06 EPS. On average, analysts forecast that China Biologic Products will post $4.33 earnings per share for the current fiscal year.

In other China Biologic Products news, CFO Ming Yang sold 21,092 shares of China Biologic Products stock in a transaction on Monday, August 15th. The stock was sold at an average price of $124.32, for a total transaction of $2,622,157.44. Following the sale, the chief financial officer now owns 24,782 shares of the company’s stock, valued at approximately $3,080,898.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Wenfang Liu sold 2,900 shares of China Biologic Products stock in a transaction on Monday, August 15th. The shares were sold at an average price of $124.32, for a total value of $360,528.00. Following the sale, the director now directly owns 3,383 shares in the company, valued at approximately $420,574.56. The disclosure for this sale can be found here. 2.68% of the stock is owned by corporate insiders.

Hedge funds have recently made changes to their positions in the stock. Capital Research Global Investors increased its stake in shares of China Biologic Products by 42.5% in the second quarter. Capital Research Global Investors now owns 3,031,654 shares of the biopharmaceutical company’s stock valued at $322,325,000 after buying an additional 904,377 shares during the last quarter. Capital World Investors increased its stake in shares of China Biologic Products by 0.7% in the second quarter. Capital World Investors now owns 2,888,482 shares of the biopharmaceutical company’s stock valued at $307,103,000 after buying an additional 21,159 shares during the last quarter. Baillie Gifford & Co. acquired a new stake in shares of China Biologic Products during the second quarter valued at $155,307,000. FMR LLC increased its stake in shares of China Biologic Products by 3.3% in the second quarter. FMR LLC now owns 1,415,606 shares of the biopharmaceutical company’s stock valued at $150,507,000 after buying an additional 44,575 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of China Biologic Products by 7.3% in the second quarter. Bank of New York Mellon Corp now owns 507,518 shares of the biopharmaceutical company’s stock valued at $53,959,000 after buying an additional 34,308 shares during the last quarter. 71.75% of the stock is currently owned by hedge funds and other institutional investors.

About China Biologic Products

China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates in the manufacture and sales of human plasma products segment. It has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across over nine categories.

Related posts

Leave a Comment